Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) – Investment analysts at HC Wainwright reduced their FY2027 earnings per share estimates for shares of Nanobiotix in a note issued to investors on Friday, September 25th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.76 per share for the year, down from their prior estimate of $0.84. The consensus estimate for Nanobiotix’s current full-year earnings is ($0.16) per share.
NBTX has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Leerink Partners upped their target price on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. Finally, Guggenheim started coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.67.
Nanobiotix Trading Down 2.1%
Nanobiotix stock opened at $32.60 on Monday. The business’s 50-day simple moving average is $38.67 and its two-hundred day simple moving average is $37.30. Nanobiotix has a fifty-two week low of $14.78 and a fifty-two week high of $57.14.
Nanobiotix Company Profile
Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.
Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.
Recommended Stories
- Five stocks we like better than Nanobiotix
- Six Flags Launches FlexPay—Is There Any FUN Left in the Stock?
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
